Argitalpenak (64) FERNANDO ANDRÉS RODRÍGUEZ-TRELLES argitalpenak

2021

  1. A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders

    European Neuropsychopharmacology, Vol. 48, pp. 49-88

2019

  1. European regulators’ views on a wearable-derived performance measurement of ambulation for Duchenne muscular dystrophy regulatory trials

    Neuromuscular Disorders, Vol. 29, Núm. 7, pp. 514-516

2016

  1. Identification and validation of biomarkers for autism spectrum disorders

    Nature Reviews Drug Discovery

  2. Perspectiva futura de la farmacoepidemiología en la era del "big data" y la expansión de las fuentes de información

    Revista Espanola de Salud Publica, Vol. 90

2015

  1. Clinical-epidemiological profile of patients initiating intensive statin therapy for the secondary prevention of vascular disease in Spain

    Revista Espanola de Salud Publica, Vol. 89, Núm. 2, pp. 159-171

  2. Prevención primaria de las enfermedades cardiovasculares con estatinas en pacientes con diabetes

    Medicina Clinica

  3. Psychiatric diseases moving towards adolescents and children: How much room is there for extrapolation?

    European Neuropsychopharmacology, Vol. 25, Núm. 7, pp. 1039-1044

  4. Statins Use and Risk of Cataracts: Firm Conclusions Are Still Far Off

    Journal of Cardiovascular Pharmacology and Therapeutics

2014

  1. Sex as a variable in medicines assessment reports for licensing in the European Union. Can gender bias be excluded?

    European Journal of Clinical Pharmacology, Vol. 70, Núm. 5, pp. 519-525

  2. Standard and intensive lipid-lowering therapy with statins for the primary prevention of vascular diseases: A population-based study

    European Journal of Clinical Pharmacology, Vol. 70, Núm. 1, pp. 99-108

2012

  1. Editorial

    European Neuropsychopharmacology

  2. The placebo arm in clinical studies for treatment of Psychiatric Disorders: A Regulatory Dilemma

    European Neuropsychopharmacology, Vol. 22, Núm. 11, pp. 804-811

  3. Typical investigational medicinal products follow relatively uniform regulations in 10 European Clinical Research Infrastructures Network (ECRIN) countries

    Trials, Vol. 13

2010

  1. Compassionate use of interventions: Results of a European Clinical Research Infrastructures Network (ECRIN) survey of ten European countries

    Trials, Vol. 11

  2. Recomendaciones para el estudio y evaluación de las diferencias de género en los ensayos clínicos de fármacos en España

    Medicina Clinica, Vol. 135, Núm. 3, pp. 130-134

2009

  1. Common definition for categories of clinical research: A prerequisite for a survey on regulatory requirements by the European Clinical Research Infrastructures Network (ECRIN)

    Trials, Vol. 10, pp. 95

  2. New regulation on drug access under special circumstances in Spain

    Medicina Clinica, Vol. 133, Núm. 11, pp. 427-432

2008

  1. Women participation in clinical trials. A preliminary study in the files of the Spanish Agency for Medicinal Products and Medical Devices

    Revista Espanola de Salud Publica, Vol. 82, Núm. 3, pp. 343-350

2004

  1. Albuminuria as a surrogate marker for drug development: A European Regulatory perspective

    Kidney International, Supplement, Vol. 66, Núm. 92

  2. Discovery and development of molecularly targeted drugs: Regulatory perspectives

    Journal of Chemotherapy